5/27/2009 | SS | Market Commentary: Amylin gives up two board seats; AOL spinoff buzz increases; Cougar lacks counter bids
|
12/31/2008 | SS | Omrix now part of Johnson & Johnson
|
12/24/2008 | SS | Market Commentary: Johnson & Johnson tender offer for Omrix expires Friday; Emageon buyout lacks financing
|
12/22/2008 | SS | Market Commentary: Johnson & Johnson, King Pharma buyouts considered done deals; InfoGroup founder explores sale
|
12/19/2008 | SS | Johnson & Johnson extends tender offer for Omrix
|
12/18/2008 | SS | Omrix shareholder Gabelli buys 1.28 million shares
|
12/12/2008 | SS | Market Commentary: PNC, NatCity await Fed blessing; tender for Mentor opens; Rodman & Renshaw sticks to takeover target
|
12/11/2008 | SS | Johnson & Johnson, Omrix merger granted approval in Israel; tender offer ends Dec. 23
|
11/25/2008 | SS | Johnson & Johnson begins tender offer for Omrix
|
11/24/2008 | SS | Johnson & Johnson to buy Omrix for $438 million
|
11/24/2008 | SS | Market Commentary: Citi rescue sparks rally; King takes Alpharma for $37 a share; J&J to buy Omrix; LandAmerica sinks
|
11/7/2006 | BT | Market Commentary: Catalyst cuts IPO price in half; Cytogen off on PIPE; Targeted Genetics gains 35%; Iomai better
|
11/7/2006 | BT | Omrix: third-quarter total revenues up 137% at $18.3 million
|
10/16/2006 | BT | Omrix: human thrombin demonstrates similar efficacy to bovine thrombin
|
10/16/2006 | BT | Market Commentary: Vical up on PIPE; Amgen sinks on FDA delay; Critical up 16%; Omrix off 14.5% on profit taking
|
8/16/2006 | BT | Omrix, FFF enter into a letter of agreement concerning Omrigam NF
|
8/7/2006 | BT | Omrix hires S&A Design to build new manufacturing plant
|
8/2/2006 | BT | Market Commentary: Pozen pumped by partnership; Biovail battered by patent loss; Gene Logic gains on layoffs
|
7/10/2006 | BT | Omrix gets FDA approval for Evicel in liver surgery
|
6/26/2006 | BT | Omrix fully enrolls phase 3 trial of Thrombin
|
5/8/2006 | BT | Omrix greenshoe exercised, raising size of IPO to $39.5 million
|
5/5/2006 | BT | Market Commentary: Northstar Neuroscience stock climbs on upsized IPO; Praecis stock jumps 22.3% on earnings
|
4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
4/17/2006 | BT | Market Commentary: Invitrogen falls on lower sales forecast; Alkermes rises, dips; Targacept, Vanda gain; Dyax off
|
4/12/2006 | BT | Market Commentary: Vanda, Targacept tank on debut; Omrix IPO in limbo; Novavax, KOS climb; Discovery soars after hours
|
3/24/2006 | BT | Omrix Biopharmaceuticals sets IPO price target at $15 to $17
|
1/18/2006 | BT | Omrix Biopharmaceuticals files for $80.5 million IPO
|